Repositioning the existing drugs for neuroinflammation: a fusion of computational approach and biological validation to counter the Parkinson’s disease progression-Reference-Cited by-同舟云学术

Repositioning the existing drugs for neuroinflammation: a fusion of computational approach and biological validation to counter the Parkinson’s disease progression

Published:2023-08-04 Issue: Volume: Page:
ISSN:1381-1991
Container-title:Molecular Diversity
language:en
Short-container-title:Mol Divers

Author:

Tiwari Harshita,Kumar Amit,Barik Manas Ranjan,Kaur Harjot,Mahajan Shubham,Shukla Monu Kumar,Gupta Monika,Yadav Govind,Nargotra Amit

Funder

Indian Council of Medical Research

Publisher

Springer Science and Business Media LLC

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Drug Discovery,Molecular Biology,General Medicine,Information Systems,Catalysis

Link

https://link.springer.com/content/pdf/10.1007/s11030-023-10708-5.pdf

Reference57 articles.

1. Rossi A, Berger K, Chen H et al (2018) Projection of the prevalence of Parkinson’s disease in the coming decades: revisited. Mov Disord 33:156–159. https://doi.org/10.1002/mds.27063

2. Goedert M, Compston A (2018) Parkinson’s disease - the story of an eponym. Nat Rev Neurol 14:57–62. https://doi.org/10.1038/nrneurol.2017.165

3. de Miranda BR, Greenamyre JT (2017) Etiology and Pathogenesis of Parkinson’s Disease. Oxidative Stress and Redox Signalling in Parkinson’s Disease. The Royal Society of Chemistry, London, pp 1–26

4. Mischley LK, Standish LJ, Weiss NS et al (2016) Glutathione as a biomarker in Parkinson’s Disease: associations with aging and disease severity. Oxid Med Cell Longev 2016:1–6. https://doi.org/10.1155/2016/9409363

5. Warner TT, Schapira AHV (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53:S16–S25. https://doi.org/10.1002/ana.10487